Merz, M., Bertsch, U., Mai, E. K., Hose, D., Schurich, B., & Goldschmidt, H. (2014). Subcutaneous versus intravenous bortezomib in two different induction therapies for fewly diagnosed multiple myeloma: Elektronische Ressource$dsubgroup analysis from the GMMG-MM5 trial. Blood, 124(21), .
Chicago-Zitierstil (17. Ausg.)Merz, Maximilian, Uta Bertsch, Elias K. Mai, Dirk Hose, Bärbel Schurich, und Hartmut Goldschmidt. "Subcutaneous Versus Intravenous Bortezomib in Two Different Induction Therapies for Fewly Diagnosed Multiple Myeloma: Elektronische Ressource$dsubgroup Analysis from the GMMG-MM5 Trial." Blood 124, no. 21 (2014).
MLA-Zitierstil (9. Ausg.)Merz, Maximilian, et al. "Subcutaneous Versus Intravenous Bortezomib in Two Different Induction Therapies for Fewly Diagnosed Multiple Myeloma: Elektronische Ressource$dsubgroup Analysis from the GMMG-MM5 Trial." Blood, vol. 124, no. 21, 2014.